Targeting the Ubiquitin - Proteasome Pathway

Synopsis

Protein turnover is crucial in maintaining cellular homeostasis and this process is largely controlled by the Ubiquitin Proteasome Pathway (UPP). The pathway consists of an enzymatic cascade that links the polypeptide cofactor Ubiquitin to specific protein targets, which mark them for degradation by the proteasome. This cascade is highly regulated and impacts virtually all cellular processes including cell cycle progression, cell proliferation, cell differentiation and apoptosis. Malfunction of the UPP has been implicated in the development of diseases such as cancer, immune disorders and neurodegeneration. 
The ability to understand and manipulate the UPP is a major objective in being able to manage disease biology. While the validity of this approach was first exemplified by the proteasome inhibitor bortezomib, approved by the FDA in 2003 and used in the treatment of multiple myeloma and mantle cell lymphoma, subsequent advances in understanding the role of different components in the UPP have allowed the development of other high quality chemical probes and inhibitors.
This meeting aims to showcase recent innovations by scientists working in both academia and industry in this exciting and rapidly expanding field.

Attendees

SCI Members attending this meeting are able to claim CPD points

Programme

10.00 Registration and refreshments
   
10.25 Opening remarks
   
10.30 PROTACs: Induced Protein Degradation as a Therapeutic Strategy
Craig Crews, Yale Center for Molecular Discovery
   
11.30 Ubiquitin system modulation: strategies and technologies 
Satpal Virdee, University of Dundee
   
12.00 Chemical Ubiquitination 
Huib Ovaa, Leiden University Medical Centre
   
12.30 Lunch and exhibition
   
14.00 From Pan-Kinase Promiscuity to Selective Degradation using PROTACs
Christopher Tinworth, GlaxoSmithKline
   
14.30 Inhibitors of the E2 ubiquitin conjugating enzyme Rad6: discovery and anticancer properties
Andrew Westwell, Cardiff University
   
15.00 Refreshments and exhibition
   
15.30 Enabling and supporting ubiquitin system targeted drug discovery
Jason Brown, Ubiquigent
   
16.00 Ubiquitin -Omics for Target Discovery in Human Disease
Benedikt Kessler, Nuffield Department of Medicine
   
16.30 Protein Degradation by In-​Cell Self-​Assembly of Proteolysis Targeting Chimeras
Tom Heightman, Astex Pharmaceuticals
   
17.00 Closing remarks and conference close

Keynote speaker

Craig Crews, Yale Center for Molecular Discovery
PROTACs:  Induced Protein Degradation as a Therapeutic Strategy

Organising Committee

Nicola Chessum, The Institute of Cancer Research
David Leese, Concept Life Sciences 
Jayshree Mistry
Manisha Naik, Lilly

Delegate Fees

Standard fees after Tuesday 18 April 2017

GB£130 . . . . . . . . . . . . . . . . SCI Member 
GB£50 . . . . . . . . . . . . . . . . . SCI Student Member
GB£70 . . . . . . . . . . . . . . . . . SCI Subsidised Member
GB£170 . . . . . . . . . . . . . . . . Non-Member

SCI Platinum Corporate Members receive 25% off the above rates

Exhibitors

Ubiquigent  

Sponsors

Evotec Ltd
GSK

The Studio

The Studio , 7 Cannon Street, Birmingham, B2 5EP, United Kingdom